BeOne Medicines (NASDAQ:ONC – Get Free Report) had its price objective raised by equities researchers at JPMorgan Chase & Co. from $445.00 to $460.00 in a note issued to investors on Thursday, Benzinga reports. The firm currently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s target price would indicate a potential upside of 17.67% from the company’s current price.
A number of other equities analysts also recently weighed in on the company. TD Cowen boosted their price target on BeOne Medicines from $424.00 to $454.00 and gave the stock a “buy” rating in a research report on Thursday, August 6th. Truist Financial restated a “buy” rating and issued a $448.00 price objective (up from $420.00) on shares of BeOne Medicines in a research note on Friday, November 6th. Citigroup reaffirmed an “outperform” rating on shares of BeOne Medicines in a research report on Thursday, August 6th. Royal Bank Of Canada lifted their target price on BeOne Medicines from $459.00 to $465.00 and gave the stock an “outperform” rating in a research note on Friday, November 6th. Finally, Weiss Ratings upgraded BeOne Medicines from a “buy (b-)” rating to a “buy (b)” rating in a research note on Monday. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $441.64.
Check Out Our Latest Analysis on ONC
BeOne Medicines Stock Performance
BeOne Medicines (NASDAQ:ONC – Get Free Report) last issued its earnings results on Thursday, November 5th. The company reported $3.64 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.34 by $1.30. BeOne Medicines had a net margin of 13.86% and a return on equity of 19.04%. The company had revenue of $1.89 billion for the quarter, compared to analysts’ expectations of $1.76 billion. As a group, equities analysts forecast that BeOne Medicines will post 9.98 earnings per share for the current year.
Insider Activity at BeOne Medicines
In other news, SVP Chan Lee sold 1,115 shares of the firm’s stock in a transaction dated Thursday, November 5th. The shares were sold at an average price of $400.82, for a total transaction of $446,914.30. Following the completion of the sale, the senior vice president owned 455 shares in the company, valued at approximately $182,373.10. This trade represents a 71.02% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Xiaodong Wang sold 38,287 shares of BeOne Medicines stock in a transaction dated Tuesday, September 8th. The stock was sold at an average price of $349.10, for a total transaction of $13,365,991.70. Following the sale, the insider directly owned 6,079 shares of the company’s stock, valued at $2,122,178.90. The trade was a 86.30% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 135,571 shares of company stock valued at $48,487,792 over the last three months. Company insiders own 6.19% of the company’s stock.
Institutional Investors Weigh In On BeOne Medicines
Hedge funds have recently bought and sold shares of the stock. Mather Group LLC. increased its holdings in shares of BeOne Medicines by 192.0% during the third quarter. Mather Group LLC. now owns 73 shares of the company’s stock worth $27,000 after purchasing an additional 48 shares during the period. GAMMA Investing LLC boosted its stake in shares of BeOne Medicines by 39.5% in the third quarter. GAMMA Investing LLC now owns 120 shares of the company’s stock valued at $44,000 after buying an additional 34 shares during the period. Allworth Financial LP boosted its stake in shares of BeOne Medicines by 101.3% in the third quarter. Allworth Financial LP now owns 153 shares of the company’s stock valued at $56,000 after buying an additional 77 shares during the period. Parallel Advisors LLC boosted its stake in shares of BeOne Medicines by 24.0% in the first quarter. Parallel Advisors LLC now owns 351 shares of the company’s stock valued at $104,000 after buying an additional 68 shares during the period. Finally, Provenance Wealth Advisors LLC acquired a new stake in BeOne Medicines during the third quarter worth approximately $106,000. 48.55% of the stock is currently owned by institutional investors and hedge funds.
BeOne Medicines Company Profile
BeOne Medicines, formerly known as BeiGene, is a global biotechnology company focused on discovering, developing, manufacturing and commercializing cancer medicines. Founded in Beijing in 2010, the company has expanded its research and commercial operations across multiple regions, including the United States, Europe and Asia. Its marketed products include Brukinsa (zanubrutinib), a targeted therapy for certain blood cancers, and Tevimbra (tislelizumab), an immunotherapy used to treat several types of cancer.
Recommended Stories
- Five stocks we like better than BeOne Medicines
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
- Lazard’s New ETF Targets Monthly Income With Junk Bonds
Receive News & Ratings for BeOne Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeOne Medicines and related companies with MarketBeat.com's FREE daily email newsletter.
